Newer Treatment Approaches for Type 2 Diabetes Mellitus

dc.contributor.advisorPórszász, Róbert
dc.contributor.advisordeptDebreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézethu_HU
dc.contributor.authorMariadasan, Lydia
dc.contributor.departmentDE--Általános Orvostudományi Karhu_HU
dc.contributor.opponentDrimba, László
dc.contributor.opponentSzentmiklósi, József András
dc.contributor.opponentdeptDebreceni Egyetemhu_HU
dc.contributor.opponentdeptKenézy Kórház Aneszteziológiai és Intenziv Therápiás Intézethu_HU
dc.contributor.opponentdeptDebreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézethu_HU
dc.date.accessioned2015-11-16T09:19:02Z
dc.date.available2015-11-16T09:19:02Z
dc.date.created2015-02
dc.description.abstractType 2 diabetes mellitus is a chronic metabolic disorder that results from defects in both insulin secretion and insulin action. Type 2 diabetes can initially be treated with oral agent monotherapy, but due to the progressive nature of this disorder, patients eventually require the addition of other oral agents, often as a prelude to insulin therapy. Several new approaches are developed to improve glycemic control with minimum side effects.hu_HU
dc.description.courseáltalános orvoshu_HU
dc.description.courselangangolhu_HU
dc.description.degreeegységes, osztatlanhu_HU
dc.format.extent40hu_HU
dc.identifier.urihttp://hdl.handle.net/2437/218340
dc.language.isoenhu_HU
dc.subjectdiabetes mellitus type 2hu_HU
dc.subjectanti-diabetic drugs
dc.subjectsulfonylureas
dc.subjectrapid-acting insulin secretagogues
dc.subjectmetformin
dc.subjectthiazolidinediones
dc.subjectα-glucosidase inhibitors
dc.subjectincretin analogue based therapies 19 glucagon-like-peptide-1 receptor agonist
dc.subjectdipeptidyl peptidase-4 inhibitors
dc.subjectsodium-glucose co-transporter type 2 inhibitors
dc.subjectpramlintide
dc.subject.dspaceUNL Thread List::Medicinehu_HU
dc.titleNewer Treatment Approaches for Type 2 Diabetes Mellitushu_HU
Fájlok